145 related articles for article (PubMed ID: 37714429)
1. Reconceptualizing podocyte damage in Fabry disease: new findings identify α-synuclein as a putative therapeutic target.
Germain DP
Kidney Int; 2024 Feb; 105(2):237-239. PubMed ID: 37714429
[No Abstract] [Full Text] [Related]
2. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy.
Braun F; Abed A; Sellung D; Rogg M; Woidy M; Eikrem O; Wanner N; Gambardella J; Laufer SD; Haas F; Wong MN; Dumoulin B; Rischke P; Mühlig A; Sachs W; von Cossel K; Schulz K; Muschol N; Gersting SW; Muntau AC; Kretz O; Hahn O; Rinschen MM; Mauer M; Bork T; Grahammer F; Liang W; Eierhoff T; Römer W; Hansen A; Meyer-Schwesinger C; Iaccarino G; Tøndel C; Marti HP; Najafian B; Puelles VG; Schell C; Huber TB
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37014703
[TBL] [Abstract][Full Text] [Related]
3. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
[TBL] [Abstract][Full Text] [Related]
4. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
5. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
[TBL] [Abstract][Full Text] [Related]
6. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
[TBL] [Abstract][Full Text] [Related]
7. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
Skrunes R; Svarstad E; Kampevold Larsen K; Leh S; Tøndel C
Nephrol Dial Transplant; 2017 May; 32(5):807-813. PubMed ID: 27190352
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
Skrunes R; Tøndel C; Leh S; Larsen KK; Houge G; Davidsen ES; Hollak C; van Kuilenburg ABP; Vaz FM; Svarstad E
Clin J Am Soc Nephrol; 2017 Sep; 12(9):1470-1479. PubMed ID: 28625968
[TBL] [Abstract][Full Text] [Related]
9. [Fabry disease].
Jakubowska E; Ryba M; Hruby Z
Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
[TBL] [Abstract][Full Text] [Related]
10. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
[No Abstract] [Full Text] [Related]
11. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
12. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease.
Prabakaran T; Nielsen R; Larsen JV; Sørensen SS; Feldt-Rasmussen U; Saleem MA; Petersen CM; Verroust PJ; Christensen EI
PLoS One; 2011; 6(9):e25065. PubMed ID: 21949853
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
Najafian B; Tøndel C; Svarstad E; Gubler MC; Oliveira JP; Mauer M
J Am Soc Nephrol; 2020 Apr; 31(4):865-875. PubMed ID: 32127409
[TBL] [Abstract][Full Text] [Related]
14. [Fabry disease from the neurologist's point of view: is it a rare cause of strokes?].
Marti-Martinez S; Climent V; Pampliega-Perez A; Martin-Estefania C; Leiva-Santana C
Rev Neurol; 2015 Jan; 60(2):93-5. PubMed ID: 25583594
[No Abstract] [Full Text] [Related]
15. Dysregulated autophagy contributes to podocyte damage in Fabry's disease.
Liebau MC; Braun F; Höpker K; Weitbrecht C; Bartels V; Müller RU; Brodesser S; Saleem MA; Benzing T; Schermer B; Cybulla M; Kurschat CE
PLoS One; 2013; 8(5):e63506. PubMed ID: 23691056
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
17. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
[TBL] [Abstract][Full Text] [Related]
18. [Recent therapeutics for Fabry disease].
Etou Y
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):875-82. PubMed ID: 19469078
[No Abstract] [Full Text] [Related]
19. [The Fabry nephropathy: new insight in diagnosis, monitoring and treatment].
Mignani R
G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373466
[TBL] [Abstract][Full Text] [Related]
20. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]